Protective Effects of Mesenchymal Stromal Cells on Adriamycin-Induced Minimal Change Nephrotic Syndrome in Rats and Possible Mechanisms.

Junqi Guo,Yuhua Zou,Zhixian Wu,Weizhen Wu,Zizhong Xu,Heyi Hu,Lianghu Huang,Huiyue Dong,Jin Chen,Jun Lu,Yunfen Fu,Jin Wang,Yujie Ma,Xiaowen Chen,Fuqiang He,Shunliang Yang,Lianming Liao,Jian Chen,Feng Zheng,Jianming Tan

DOI: https://doi.org/10.1016/j.jcyt.2013.08.002

IF: 6.196

2014-01-01

Cytotherapy

Abstract:Background aims. Minimal change nephrotic syndrome is the most frequent cause of nephrotic syndrome in childhood. Current treatment regimes, which include glucocorticoid hormones and immunosuppressive therapy, are effective and have fast response. However, because of the side effects, long treatment course, poor patient compliance and relapse, novel approaches for the disease are highly desired. Methods. The adriamycin-induced nephrotic rat model was established. Rats were allocated to a model group, a prednisone group or mesenchymal stromal cell (MSC) group. Clinical parameters in each treatment group were determined at 2 weeks, 4 weeks and 8 weeks. The messenger RNA (mRNA) levels of synaptopodin, p21 and monocyte chemoattractant protein-1 were determined through the use of quantitative real-time polymerase chain reaction. Protein levels were determined by means of Western blot or enzyme-linked immunosorbent assay. Podocytes were isolated and apoptotic rate after adriamycin with or without MSC treatment was analyzed by means of flow cytometry. Results. MSC intervention improved renal function as assessed by urinary protein, blood creatinine and triglyceride levels. MSC intervention reduced adriamycin-induced renal tissue damage visualized by immunohistochemistry and light and electron microscopic analysis and reduced adriamycin-induced podocyte apoptosis. After MSC intervention, mRNA and protein levels of synaptopodin and p21 in renal cortex were significantly increased. MSCs also restored synaptopodin mRNA and protein expression in isolated podocytes. In addition, monocyte chemoattractant protein-1 mRNA in renal cortex and protein level in serum of the MSC treatment group were significantly decreased compared with that in the adriamycin-induced nephropathy model group. Conclusions. Our data indicate that MSCs could protect rats from adriamycin-induced minimal change nephrotic syndrome, and the protective effects of MSCs are mediated through multiple actions.